Core Insights - Summit Therapeutics Inc.'s partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial, which evaluates ivonescimab in combination with platinum-based chemotherapy against tislelizumab plus chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC) [1][3] Group 1: Trial Details - The HARMONi-6 trial is sponsored by Akeso and conducted in China, with all data managed and analyzed by Akeso [2] - The trial met its primary endpoint of progression-free survival (PFS), showing a statistically significant improvement in PFS for ivonescimab plus chemotherapy compared to BeiGene's tislelizumab plus chemotherapy [3][4] - The PFS benefit was observed in both PD-L1-positive and PD-L1-negative tumor patients, with no new safety signals identified in the study [4] Group 2: Future Developments - Full data from the HARMONi-6 trial will be presented at a major medical conference later this year [4] - Summit Therapeutics is currently enrolling patients in the HARMONi-3 Phase 3 study to evaluate ivonescimab combined with chemotherapy against Merck's Keytruda [5] - In September 2024, Summit released data from the primary analysis of the Phase 3 HARMONi-2 trial, which also showed significant PFS improvement for ivonescimab compared to pembrolizumab [6] Group 3: Collaborations and Market Impact - Summit announced a clinical trial collaboration with Pfizer to evaluate ivonescimab with Pfizer's antibody-drug conjugates across multiple solid tumor settings [6][7] - Under the agreement, Summit will provide ivonescimab, while Pfizer will manage the studies, with both companies retaining rights to their products [7] - Following the news, SMMT stock increased by 21.11% to $33.11 [7]